Coinbase’s fight over new crypto market rules has shifted toward a surprising target. Citron Research claimed the exchange fears tokenization rival Securitize moreCoinbase’s fight over new crypto market rules has shifted toward a surprising target. Citron Research claimed the exchange fears tokenization rival Securitize more

Citron Research Says Coinbase Dropped CLARITY to Block Tokenization Rival Securitize

Coinbase’s fight over new crypto market rules has shifted toward a surprising target. Citron Research claimed the exchange fears tokenization rival Securitize more than unclear regulation. 

The short seller argued that Coinbase pulled back support for the CLARITY Act because cleaner rules could strengthen competitors. The dispute surfaced as Securitize moves closer to public markets through a planned SPAC merger with Cantor Equity Partners II.

Citron Claims Coinbase Wants Control, Not Competition

Citron Research criticized Coinbase CEO Brian Armstrong after he discussed tokenized assets on CNBC. The firm said Coinbase wants lawmakers to clarify crypto rules while limiting rivals. Hence, Citron framed Coinbase’s stance as defensive rather than industry focused.

Citron argued that Coinbase earns meaningful revenue from stablecoin yield programs. Consequently, it claimed Coinbase fears losing that edge if tokenized securities grow faster. Tokenized equities could unlock new trading options for investors. However, they could also reduce Coinbase’s influence in key areas.

Coinbase withdrew support for the CLARITY Act late Wednesday. The company said the bill could block tokenized equity products in practice. Additionally, the Senate Banking Committee canceled a scheduled markup session shortly after.

Securitize Holds Licenses and Moves Toward a SPAC Listing

Securitize operates as a tokenization platform that focuses on securities. Citron said that model already fits existing legal frameworks. Moreover, it argued the firm holds the licenses needed to issue tokenized securities. That gives Securitize an advantage if lawmakers create clearer rules.

Securitize has already issued more than $4 billion worth of tokenized assets. Besides, it has support from major financial names. Citron highlighted BlackRock as a key backer. It described the situation as a clash between Coinbase and powerful Wall Street allies.

Wider Battle Over Tokenized Markets

The clash adds pressure to the debate around tokenized equities in the United States. Tokenized shares could shorten settlement times and expand access. Significantly, they could also reshape how investors lend and trade securities.

Coinbase sits in a complicated spot in that race. Coinbase Ventures invested in Securitize during a 2018 fundraising round. However, Citron suggested the strategic alignment has shifted as tokenization moves mainstream.

Cantor Equity Partners II plans to take Securitize public through a SPAC deal. The timeline points to the first half of 2026.

Market Opportunity
Blockstreet Logo
Blockstreet Price(BLOCK)
$0.014743
$0.014743$0.014743
-0.72%
USD
Blockstreet (BLOCK) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26